Diabetic macular edema (DME) is one of the main causes of blindness globally. To address this challenge, we must have access to the best tools available – and match them to appropriate patients. One such tool is ILUVIEN® (fluocinolone acetonide intravitreal implant), indicated for the treatment of vision impairment associated with chronic diabetic macular oedema, considered insufficiently responsive to available therapies (i.e. DME that persists or recurs despite treatment). A recent conference in Rome (ILUVIEN Medical Expert User Group Meeting - an Alimera Sciences promotional meeting) on November 17, 2018 gathered international experts to discuss best practice and real-world experience with this sustained-release steroid implant.
